Bisoprolol Fumarate

PreclinicalSmall molecule

IIPCA Laboratories Ltd.

Bisoprolol Fumarate is one of 18 small molecule programs targeting Metabolism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetabolismCompleted

MetabolismPreclinical

Completed

Competition

Competitive Landscape

26 competitors in Metabolism

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 3

1 2

Aricept

Eisai

Phase 2

1 3

Cymbalta

Jazz Pharmaceuticals

Phase 1

2 4

Bayer Aspirin

Bayer

Phase 1

1 5

Atropen

FFresenius Kabi Taiwan Ltd.

Phase 1

1 6

Tasmar

BBausch Health Americas, Inc.

Phase 1

1 7

Exendin-(9-39)

EEiger BioPharmaceuticals

Phase 1

3 8

Quemliclustat

Arcus Biosciences

Phase 1

1 9

Obicetrapib

NNewAmsterdam Pharma

Phase 1

1 10

Dilantin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Adjuvant

NCT06643221

Clinical

Trials by Indication[1]

Metabolism1 trial

Activation of Brown Adipose Tissue Metabolism Using Mirabegron

Completed·UUniversité de Sherbrooke·N/A·NCT04823442·9 enrolled

Adjuvant1 trial

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting·UUniversity of Arizona·Phase 1·NCT06643221·100 enrolled

Fed1 trial

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition

Completed·IIPCA Laboratories Ltd.·Phase 1·NCT01744873·24 enrolled

Insulin resistance1 trial

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

Completed·UUkrainian Medical Stomatological Academy·Phase 4·NCT03011775·43 enrolled

Drug Interactions1 trial

Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS

Completed·—·Phase 2·NCT05536284·128 enrolled

3 more indications

Cardiomyopathy1 trial

Bisoprolol in DMD Early Cardiomyopathy

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT03779646·42 enrolled

Acute Coronary Syndrome1 trial

Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome

Completed·—·Phase 2·NCT05536271·127 enrolled

Unspecified1 trial

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition

Completed·IIPCA Laboratories Ltd.·Phase 1·NCT01741623·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bisoprolol Fumarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisoprolol Fumarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisoprolol Fumarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IPCA Laboratories Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIPCA Laboratories Ltd.

Bisoprolol Fumarate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metabolism1 trial

Adjuvant1 trial

Fed1 trial

Insulin resistance1 trial

Drug Interactions1 trial

Cardiomyopathy1 trial

Acute Coronary Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News